Trial Profile
A phase Ib/II clinical study evaluating the safety and preliminary efficacy of IMCgp100 in combination with galunisertib in metastatic cutaneous melanoma
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 01 Jul 2015
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Tebentafusp (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Jul 2015 New trial record
- 29 Jun 2015 According to a company media release, Immunocore and Eli Lilly plan to initiate this study in 2016.